Amalgamated Bank’s Kura Oncology KURA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-2,533
Closed -$26K 2260
2025
Q4
$26K Buy
2,533
+34
+1% +$357 ﹤0.01% 2014
2025
Q3
$22K Hold
2,499
﹤0.01% 2079
2025
Q2
$14K Hold
2,499
﹤0.01% 2275
2025
Q1
$16K Hold
2,499
﹤0.01% 2155
2024
Q4
$22K Hold
2,499
﹤0.01% 2085
2024
Q3
$49K Hold
2,499
﹤0.01% 1852
2024
Q2
$51K Buy
2,499
+100
+4% +$2.06K ﹤0.01% 1850
2024
Q1
$51K Sell
2,399
-3,763
-61% -$73.2K ﹤0.01% 1864
2023
Q4
$89K Sell
6,162
-662
-10% -$6.51K ﹤0.01% 2040
2023
Q3
$62K Buy
6,824
+451
+7% +$4.58K ﹤0.01% 2162
2023
Q2
$67K Sell
6,373
-497
-7% -$5.88K ﹤0.01% 2204
2023
Q1
$84K Sell
6,870
-1,469
-18% -$18.3K ﹤0.01% 2121
2022
Q4
$103K Buy
8,339
+244
+3% +$3.55K ﹤0.01% 2119
2022
Q3
$111K Buy
8,095
+79
+1% +$1.22K ﹤0.01% 2104
2022
Q2
$147K Buy
8,016
+366
+5% +$5.26K ﹤0.01% 2010
2022
Q1
$123K Buy
+7,650
New +$110K ﹤0.01% 2120
2021
Q2
Sell
-8,831
Closed -$250K 2180
2021
Q1
$250K Sell
8,831
-724
-8% -$22.9K 0.01% 1358
2020
Q4
$312K Buy
9,555
+1,305
+16% +$45.9K 0.01% 1208
2020
Q3
$253K Buy
+8,250
New +$182K 0.01% 1197

Other funds holding KURA

Amalgamated Bank's KURA Position: Q1 2026 in Review

Amalgamated Bank sold out of Kura Oncology (KURA) in Q1 2026, closing a stake of 2,533 shares — an estimated $26K sold.

Amalgamated Bank first reported a position in KURA in Q3 2020 and held it in 19 quarters. The position peaked at $312K in Q4 2020. 222 funds tracked by Wall St. Rank hold KURA as of Q1 2026.

  • Amalgamated Bank reported no remaining Kura Oncology position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 2,533 Kura Oncology shares in Q1 2026, an estimated $26K.
  • Amalgamated Bank first reported a position in Kura Oncology in Q3 2020 and held it in 19 quarters.
  • Amalgamated Bank's Kura Oncology position peaked at $312K in Q4 2020.
  • 222 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.